Changes in hematological parameters after switching treatment of HIV-infected patients from zidovudine to abacavir or tenofovir DF.
Viergever
Roderik F
RF
ten Berg
Maarten J
MJ
van Solinge
Wouter W
WW
Hoepelman
Andy I M
AI
Gisolf
Elisabeth H
EH
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000740:Anemia / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D015224:Dideoxynucleosides / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy*; D006403:Hematologic Tests; D006801:Humans; D008297:Male; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D063065:Organophosphonates / Q000627:therapeutic use; D000068698:Tenofovir; D055815:Young Adult; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use; D000099227:Abacavir
D000225:Adenine; D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D063065:Organophosphonates; D000068698:Tenofovir; D015215:Zidovudine; D000099227:Abacavir